Crumly & Associates Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Crumly & Associates Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 114.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 979 shares of the company's stock after purchasing an additional 523 shares during the period. Crumly & Associates Inc.'s holdings in Eli Lilly and Company were worth $809,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Garner Asset Management Corp lifted its position in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after acquiring an additional 12 shares in the last quarter. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $49,534,000. Revolve Wealth Partners LLC lifted its position in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Finally, SOA Wealth Advisors LLC. lifted its position in Eli Lilly and Company by 7.1% in the 4th quarter. SOA Wealth Advisors LLC. now owns 925 shares of the company's stock valued at $714,000 after acquiring an additional 61 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $7.43 during trading on Monday, reaching $770.16. The company had a trading volume of 3,946,850 shares, compared to its average volume of 3,669,771. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The firm's 50-day simple moving average is $780.81 and its 200 day simple moving average is $800.36. The firm has a market capitalization of $729.91 billion, a price-to-earnings ratio of 62.67, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business posted $2.58 earnings per share. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Ratings Changes

Several research firms recently issued reports on LLY. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, June 7th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating and issued a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday. Finally, Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.79.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.